The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS

PURPOSE: Rapid development of novel therapeutics in renal cell carcinoma (RCC) has led to financial burden for patients and society. Value including clinical benefit, toxicity affecting quality of life and cost-effectiveness are a concern, prompting the need for tools to facilitate value assessment...

Descripción completa

Detalles Bibliográficos
Autores principales: Ha, Hyerim, Kang, Jin Hyoung, Kim, Do Yeun, Bae, Seung Jin, Lee, Hee Yeon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275027/
https://www.ncbi.nlm.nih.gov/pubmed/35821026
http://dx.doi.org/10.1186/s12913-022-08279-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275027/
https://www.ncbi.nlm.nih.gov/pubmed/35821026
http://dx.doi.org/10.1186/s12913-022-08279-6

Ejemplares similares